Berlin, September 30, 2014. nanoPET Pharma GmbH announced today that they have signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim. By developing tailor-made contrast agents for studies in both basic and pre-clinical research, nanoPET Pharma will contribute to the optimization of Boehringer Ingelheim’s imaging diagnostics. The first joint projects have already begun and many more are being planned.
After several years of close collaboration between Boehringer Ingelheim and nanoPET Pharma, there now exists a framework contract between the two companies. This contract bears a long term perspective and will include various joint projects. “This cooperation model is based on a true partnership”, explains Dr. Andreas Briel, CEO of nanoPET Pharma. “Research, development and marketing of therapeutic substances will be led by Boehringer Ingelheim; pre-clinical diagnostics will be managed by nanoPET. This ensures that the business fields remain strictly separate and that both partners benefit.”
The aim of the projects is to support Boehringer Ingelheim in the early identification of suitable drug candidates, to accelerate the process and, at the same time, to shorten the pre-clinical phase through the use of improved imaging methods. Tailor-made contrast agents enable the implementation of high-resolution in-vivo monitoring methods with resolutions down to the micrometer range in pre-clinical studies. Of importance to note is that such methods also enable a reduction in the number of laboratory animals. Indeed, during the past several years, regulatory authorities constantly demand proof of the use of modern imaging methods in drug development, during the preparation ofapproval documentation.
Dr. Andreas Briel concludes: „We provide what any pharmaceutical development company needs during the pre-clinical phase: a clear and significant image which protects the living organism. Our services support the 3R-concept of “replace, reduce and refine”.” Within this cooperation, nanoPET Pharma will also investigate, in the medium-term, opportunities for the implementation of imaging methods as companion diagnostics in human medicine.
(2,223 characters)
About nanoPET Pharma GmbH:
nanoPET Pharma GmbH, founded in 2007 and located in Berlin, Germany, explores, develops and produces various diagnostic imaging agents. A section of the company’s core business is the proprietary product line with 21 substances, which are applied in MRI, CT, ultrasound and optical imaging in pre-clinical research all over the world. Additionally, nanoPET Pharma develops specialized contrast agents for implementation in pharmaceutical research. nanoPET also focusses on positron emitting inorganic nanoparticles for molecular and cell-specific positron emission tomography (PET), a diagnostic tool that allows imaging of the human body. The market potential of this technology is estimated to lie at several hundred million Euros.
Not for publication
Contacting nanoPET Pharma GmbH:
For further information and images please contact:
Dr. Andreas Briel
nanoPET Pharma GmbH
Robert-Koch-Platz 4
D-10115 Berlin
Tel. +49 (0)30 890 49 740
Mail: andreas.briel@nanopet.de
Help employers find you! Check out all the jobs and post your resume.
